{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T18:52:57Z","timestamp":1768071177501,"version":"3.49.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec><jats:title>Purpose:<\/jats:title><jats:p>We sought to characterize the angiofibrotic and apoptotic effects of vascular endothelial growth factor (VEGF)-inhibition on fibrovascular epiretinal membranes in eyes with traction retinal detachment because of proliferative diabetic retinopathy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Membranes were excised from 20 eyes of 19 patients (10 randomized to intravitreal bevacizumab, 10 controls) at vitrectomy. Membranes were stained with antibodies targeting connective tissue growth factor (CTGF) or VEGF and colabeled with antibodies directed against endothelial cells (CD31), myofibroblasts, or retinal pigment epithelium markers. Quantitative and colocalization analyses of antibody labeling were obtained through immunofluorescence confocal microscopy. Masson trichrome staining, cell counting of hematoxylin and eosin sections, and terminal dUTP nick-end labeling staining were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>High levels of fibrosis were observed in both groups. Cell apoptosis was higher (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.05) in bevacizumab-treated membranes compared with controls. The bevacizumab group had a nonsignificant reduction in colocalization in CD31\u2013CTGF and cytokeratin\u2013VEGF studies compared with controls. Vascular endothelial growth factor in extracted membranes was positively correlated with vitreous levels of VEGF; CTGF in extracted membranes was negatively correlated with vitreous levels of CTGF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Bevacizumab suppresses vitreous VEGF levels, but does not significantly alter VEGF or CTGF in diabetic membranes that may be explained by high baseline levels of fibrosis. Bevacizumab may cause apoptosis within fibrovascular membranes.<\/jats:p><\/jats:sec>","DOI":"10.1097\/iae.0000000000001952","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T21:51:42Z","timestamp":1511905902000},"page":"265-273","source":"Crossref","is-referenced-by-count":20,"title":["APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION"],"prefix":"10.1097","volume":"39","author":[{"given":"Chunhua","family":"Jiao","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Stephen A Wynn Institute for Vision Research, University of Iowa Hospitals and Clinics, Iowa City, Iowa;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Eliott","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Spee","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikun","family":"He","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Stephen A Wynn Institute for Vision Research, University of Iowa Hospitals and Clinics, Iowa City, Iowa;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Mullins","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Stephen A Wynn Institute for Vision Research, University of Iowa Hospitals and Clinics, Iowa City, Iowa;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Hinton","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliott H.","family":"Sohn","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Stephen A Wynn Institute for Vision Research, University of Iowa Hospitals and Clinics, Iowa City, Iowa;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/09286580701396720","article-title":"Overview of epidemiologic studies of diabetic retinopathy","volume":"14","author":"Klein","year":"2007","journal-title":"Ophthalmic Epidemiol"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/archophthalmol.2012.1611","article-title":"Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1","volume":"130","author":"Sohn","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R4-20230816","first-page":"20","article-title":"Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy","volume":"2","author":"Arevalo","year":"2013","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/IAE.0b013e3181884ff4","article-title":"Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up","volume":"28","author":"Arevalo","year":"2008","journal-title":"Retina"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K","article-title":"Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy","volume":"13","author":"Miller","year":"1997","journal-title":"Diabetes Metab Rev"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4","article-title":"Angiogenesis: new insights and therapeutic potential","volume":"261","author":"Tomanek","year":"2000","journal-title":"Anat Rec"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archopht.124.10.1457","article-title":"Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye","volume":"124","author":"Kuiper","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1167\/iovs.07-1302","article-title":"Connective tissue growth factor as a mediator of intraocular fibrosis","volume":"49","author":"He","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"e2675","DOI":"10.1371\/journal.pone.0002675","article-title":"The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy","volume":"3","author":"Kuiper","year":"2008","journal-title":"PLoS One"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"R12-20230816","first-page":"CD008214","article-title":"Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy","volume":"7","author":"Smith","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-20230816","first-page":"855","article-title":"Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes","volume":"37","author":"Lopez","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ophtha.2010.08.038","article-title":"Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications","volume":"118","author":"El-Sabagh","year":"2011","journal-title":"Ophthalmology"},{"key":"R15-20230816","first-page":"36","volume":"11","author":"Abramoff","year":"2004","journal-title":"Image processing with Image J. Biophotonics International"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ophtha.2011.03.036","article-title":"The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy","volume":"118","author":"Ahn","year":"2011","journal-title":"Ophthalmology"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ajo.2006.04.058","article-title":"Intravitreal injection of bevacizumab (avastin) as adjunctive treatment of proliferative diabetic retinopathy","volume":"142","author":"Mason","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1442-9071.2008.01805.x","article-title":"Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series","volume":"36","author":"Yeoh","year":"2008","journal-title":"Clin Exp Ophthalmol"},{"key":"R19-20230816","first-page":"673","article-title":"Characterization of cells from patient-derived fibrovascular membranes in proliferative diabetic retinopathy","volume":"21","author":"Kim","year":"2015","journal-title":"Mol Vis"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/bjophthalmol-2014-305321","article-title":"Overexpression of CD163 in vitreous and fibrovascular membranes of patients with proliferative diabetic retinopathy: possible involvement of periostin","volume":"99","author":"Kobayashi","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/archopht.121.9.1283","article-title":"A role for connective tissue growth factor in the pathogenesis of choroidal neovascularization","volume":"121","author":"He","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1167\/iovs.06-0804","article-title":"Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina","volume":"48","author":"Kuiper","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth-factor in ocular fluid of patients with diabetic-retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1440-1827.2007.02162.x","article-title":"Expression of connective tissue growth factor is in agreement with the expression of VEGF, VEGF-C, -D and associated with shorter survival in gastric cancer","volume":"57","author":"Liu","year":"2007","journal-title":"Pathol Int"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1167\/iovs.04-0761","article-title":"Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress","volume":"46","author":"Matsuda","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/157339911795843104","article-title":"Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery","volume":"7","author":"Montero","year":"2011","journal-title":"Curr Diabetes Rev"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/IAE.0b013e3181bd2d7b","article-title":"Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab","volume":"30","author":"Kubota","year":"2010","journal-title":"Retina"},{"key":"R28-20230816","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ajo.2010.03.016","article-title":"Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection","volume":"150","author":"Kohno","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"30336","DOI":"10.1074\/jbc.273.46.30336","article-title":"Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase\/Akt signal transduction pathway. Requirement for Flk-1\/KDR activation","volume":"273","author":"Gerber","year":"1998","journal-title":"J Biol Chem"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.1074\/jbc.273.21.13313","article-title":"Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells","volume":"273","author":"Gerber","year":"1998","journal-title":"J Biol Chem"},{"key":"R31-20230816","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/IAE.0b013e3182753b41","article-title":"Altered vascular microenvironment by bevacizumab in diabetic fibrovascular membrane","volume":"33","author":"Nakao","year":"2013","journal-title":"Retina"},{"key":"R32-20230816","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/IAE.0b013e3181cb463a","article-title":"Fibrous membranes in diabetic retinopathy and bevacizumab","volume":"30","author":"Pattwell","year":"2010","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201902000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T05:07:25Z","timestamp":1719637645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201902000-00006"}},"subtitle":["Results of a Prospective Trial. Report No. 2"],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001952","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}